Hillhurst Biopharmaceuticals announced that the final healthy volunteer has completed the study protocol in a Phase 1 clinical trial…
Articles by Marisa Wexler, MS
A Phase 1/2 clinical trial testing Beam Therapeutics’ gene-editing therapy BEAM-101 is continuing to enroll young adults with…
Kier “Junior” Spates is hosting a new podcast to empower and educate people living with sickle cell disease. Called…
Health Canada has approved an extended-release formulation of Ferriprox (deferiprone) to treat iron overload in people with sickle cell…
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on FTX-6058, an experimental therapy that…
The risk of pregnancy-related death is about 26 times higher among people with sickle cell disease (SCD) in the…
We at Sickle Cell Anemia News have brought you coverage of the latest developments in research and advances in treatment related…
New preclinical data support the ability of the ESCAPE platform, an approach Beam Therapeutics is advancing, to more safely prepare people…
The experimental gene-editing therapy EDIT-301 appears to be working largely as expected in the first two sickle cell disease…
The Qatar Ministry of Public Health has approved Endari (L-glutamine) to treat adults and children, starting at age 5,…